Via a suitably exuberant press release at Yahoo! News, we learn that tissue engineering concern Tengion is doing well: "the company has raised $50 million in a recently completed Series B equity financing. ... Tengion plans to use the proceeds to fund human clinical trials to advance the development of its lead product, the autologous neo-bladder construct, for the treatment of neurogenic bladder associated with spina bifida and spinal cord injuries." This is representative of the funding pouring into regenerative medicine and tissue engineering these days. Development of a research infrastructure capable of building replacement organs from your cells is well under way. The next decade will be a kinder place for those with failing and age-damaged tissues, but there is still much more to be done in the fight to cure aging.